ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2020, Vol. 12 ›› Issue (2): 164-167.doi: 10.3969/j.issn.1674-3865.2020.02.020

• 临床研究 • 上一篇    下一篇

孟鲁司特钠联合干扰素α-2b对呼吸道合胞病毒感染毛细支气管炎患儿血清炎性因子水平及康复进程的影响

陈洋洋   

  1. 473000 河南 南阳，南阳市中心医院儿科
  • 收稿日期:2020-01-07 出版日期:2020-04-25 上线日期:2020-04-25
  • 通讯作者: 陈洋洋，jiong0628406upk@163.com
  • 作者简介:陈洋洋（1990-），男，主治医师。研究方向：小儿内科疾病的诊治，E-mail:jiong0628406upk@163.com

Effect of montelukast sodium combined with interferon α-2b on serum inflammatory factor levels and rehabilitation process in children with respiratory syncytial virus-infected bronchiolitis

CHEN Yangyang   

  • Received:2020-01-07 Published:2020-04-25 Online:2020-04-25
  • Contact: 陈洋洋，jiong0628406upk@163.com

PDF (PC)

77

摘要： 目的 探讨孟鲁司特钠联合干扰素α-2b对呼吸道合胞病毒感染毛细支气管炎患儿血清白细胞介素-6（IL-6）、半胱氨酸白三烯（CysLTs）、嗜酸粒细胞阳离子蛋白(ECP)、肺表面活性蛋白D（SP-D）水平及康复进程的影响。方法 选取2018年2月至2019年2月我院收治的RSV感染的毛细支气管炎患儿128例为研究对象，随机分为对照组和观察组各64例。对照组给予吸氧、退热、镇静、止咳化痰及重组人干扰素α-2b肌内注射治疗，观察组在对照组治疗基础上加用孟鲁司特钠4 mg每晚睡前口服。比较两组患儿治疗前后〖JP2〗血清IL-6、CysLTs、ECP、SP-D水平改变及临床症状缓解时间。结果 治疗前，两组患儿血清IL-6、CysLTs、ECP、SP-D水平差异无统计学意义（P>0.05），治疗后，两组患儿血清IL-6、CysLTs、ECP、SP-D水平均较治疗前下降，且观察组明显低于对照组，差异有统计学意义（P<0.05）；观察组患儿咳嗽消失时间、喘息消失时间、肺部湿啰音消失时间、氧疗时间、住院时间均明显低于对照组，差异有统计学意义（P<0.05）；观察组治疗总有效率为96.9%（62/64），高于对照组79.7%（51/64），差异有统计学意义（P<0.05）。结论 孟鲁司特钠联合干扰素α-2b对小儿呼吸道合胞病毒感染毛细支气管炎具有协同抗炎作用，可有效改善炎性因子水平，缩短康复进程，提高临床疗效。

关键词: 毛细支气管炎, 呼吸道合胞病毒, 孟鲁司特钠, 重组人干扰素α-2b, 炎性因子

Abstract: Objective To investigate the effect of montelukast sodium combined with interferon α-2b on serum interleukin-6 (IL-6), cysteine leukotriene (CysLTs), and eosinophils cationic protein(ECP), pulmonary surfactant protein D (SP-D) levels and rehabilitation process in children with respiratory syncytial virus-infected bronchiolitis.Methods A total of 128 children with RSV-infected bronchiolitis treated in our hospital from February 2018 to February 2019 were selected as the research subjects and randomly divided into a control group and an observation group of 64 cases each. The control group was given oxygen inhalation and antipyretic and sedative treatment, cough and phlegm relieving therapy, and intramuscular injection of recombinant human interferon α-2b. The observation group was treated with montelukast sodium, 4 mg orally every night before sleep in addition to the treatment for control group. Changes in serum IL-6, CysLTs, ECP and SP-D levels, and relief of clinical symptoms were compared between the two groups of children before and after treatment.Results Before treatment, there was no statistical difference in serum IL-6, CysLTs, ECP, or SP-D levels between the two groups of children(P>0.05). After treatment, serum IL-6, CysLTs, ECP, and SP-D levels in the two groups were lower than before treatment, and the observation group was significantly lower than the control group, the difference being statistically significant(P<0.05). The relief time of cough, wheezing and lung moist rales, the oxygen treatment time and the hospitalization time in the observation group were significantly lower than those in the control group, and the differences were statistically significant(P<0.05). The total effective rate in the observation group was 96.9%(62/64), which was higher than the control group(79.7%,51/64), and the difference was statistically significant(P<0.05).Conclusion Montelukast sodium combined with interferon alpha-2b has a synergistic anti-inflammatory effect on bronchiolitis caused by respiratory syncytial virus infection in children, which can effectively improve the level of inflammatory factors, shorten the rehabilitation process, and improve clinical efficacy.

Key words: Bronchiolitis, Respiratory syncytial virus, Montelukast sodium, Recombinant human interferon alpha-2b, Inflammatory factor